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ABSTRACT
Introduction Lung cancer and its treatment cause a 
wide range of symptoms impacting the patients’ health- 
related quality of life (HRQoL). The use of patient- reported 
outcomes (PRO) to monitor symptoms during and after 
cancer treatment has been shown not only to improve 
symptom management but also to improve HRQoL and 
overall survival (OS). Collectively, these results favour 
implementation of PRO- symptom monitoring in daily 
clinical care. However, these promising outcomes have 
been obtained under trial conditions in which patients 
were selected based on stringent inclusion criteria, and in 
countries with a dissimilar healthcare system than in the 
Netherlands.
The primary aim of the SYMptom monitoring with Patient- 
Reported Outcomes using a web application among 
patients with Lung cancer in the Netherlands (SYMPRO- 
Lung) study is to evaluate the effect of PRO- symptom 
monitoring during and after lung cancer treatment on 
HRQoL in daily clinical practice. Secondary objectives 
include assessing the effect of PRO- symptom monitoring 
on progression- free survival, OS, the incidence and grade 
of PRO symptoms, medication adherence, implementation 
fidelity and cost- effectiveness.
Methods and analysis The SYMPRO- Lung study is 
a prospective, multicentre trial with a stepped wedge 
cluster randomised design. Study participants (n=292 
intervention, n=292 controls) include patients with 
lung cancer (stages I–IV) starting treatment with 
surgery, systemic treatment, targeted treatment and/or 
radiotherapy.
Every participating centre will consecutively switch 
from the control period to the intervention period, in 
which patients report their symptoms weekly via an 
online tool. In the intervention group, we evaluate two 
alert approaches: the active and reactive approach. If 
the symptoms exceed a predefined threshold, an alert 
is sent to the healthcare provider (active approach) or 
to the patient (reactive approach). Both the control and 
intervention group complete HRQoL questionnaires at 4 
time points: at baseline, 15 weeks, 6 months and 1- year 
post treatment). Differences in HRQoL between the groups 
will be compared using linear mixed modelling analyses, 
accounting for within- centre clustering, potential time 
effects and confounding.
Ethics and dissemination The study protocol was 
approved by the Institutional Review Board and the 
Medical Ethics Committee of the Amsterdam UMC (under 
number NL 68440.029.18) and the institutional review 
boards of the participating study sites. The dissemination 
of the results will be conducted through publication 
in peer- reviewed journals and through scientific 
conferences.
Trial registration number Trial register identifier: 
Netherlands Trial register Trial NL7897. Date of registration: 
24 July 2019. https://www. trialregister. nl/ trial/ 7897.
Strengths and limitations of this study
 ► A pragmatic stepped- wedge design is used allowing 
revelation of the effect in the real world.
 ► This multicentre study compares the effect of an ac-
tive approach with a reactive approach.
 ► We include a heterogeneous lung cancer group 
comparable to real- world clinical practice.
 ► The use of items from the Food and Drug 
Administration (FDA)- approved Patient- Reported 
Outcome version of the Common Terminology 
Criteria for Adverse Events (CTCAE) is a perfect fit to 
the commonly used CTCAE.
 ► Most participating centres do not allow to fully in-
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INTRODUCTION
In the Netherlands, approximately 13 000 people are 
diagnosed with lung cancer each year.1 Treatment options 
include surgery, systemic treatment, targeted treatment, 
radiotherapy or a combination of these treatments. Lung 
cancer and its treatment can cause a wide range of symp-
toms including fatigue, dyspnoea, cough and pain both 
during the period of treatment and thereafter.2 These 
symptoms can have a significant impact on a patient’s 
health- related quality of life (HRQoL), and may nega-
tively affect further treatment.3 In addition, these symp-
toms can also be a signal of cancer relapse.4
The current strategy for symptom monitoring is 
primarily based on the report and grading by healthcare 
providers (HCPs). Increasing evidence suggests that this 
leads to suboptimal symptom management,5 6 since HCPs 
miss a significant proportion of the symptoms experienced 
by patients due to underestimating and underreporting 
of the onset, frequency and severity of symptoms.6–9 
Partially, this is due to the limited time typically available 
for a clinic visit. Furthermore, patients might be reluctant 
or tend to forget to contact the HCP in case of symptoms 
experienced when at home.6 7 9 Therefore, more efficient 
strategies for monitoring symptoms at home during and 
after treatment are warranted.
A potentially useful strategy is the use of an online 
patient- reported outcome (PRO) measure that monitors 
symptoms and activates an alert based on a predefined 
algorithm, which is subsequently send to the HCP. 
PRO- symptom monitoring provides improved accuracy 
in symptom assessment compared with HCP- reported 
outcomes.10 Recent randomised trials have demon-
strated that PRO- symptom monitoring does not only 
improve symptom management, but also significantly 
improves HRQoL and overall survival (OS).11–13 Basch 
et al conducted a large trial (n=766) assessing the effect 
of PRO- symptom monitoring in patients treated with 
chemotherapy for advanced solid tumours on HRQoL 
and OS.11 14 The results showed that weekly PRO- symptom 
monitoring significantly improved HRQoL compared 
with usual care. When comparing HRQoL at 6 months, 
patients in the PRO- symptom monitoring group had a 
16% improved HRQoL score from baseline compared 
with those in the standard care group. Denis et al15 also 
reported a positive effect of PRO symptom monitoring 
on HRQoL in a randomised study of 121 patients with 
lung cancer treated with systemic therapy. Six months 
post baseline, 81% of the patients in the PRO- symptom 
monitoring group had a significantly improved or stable 
HRQoL score versus 59% of patients in the control 
group. Furthermore, disease recurrence was detected 
earlier, and patients in the PRO- symptom monitoring 
group had a better performance status compared with 
patients receiving usual care.13 Both of these trials found 
a significantly improved OS in the PRO- symptom moni-
toring group, with a survival benefit ranging from 5 to 
7 months.14 PRO- symptom monitoring as well demon-
strated positive results in other fields of oncology and 
outside the field of oncology.16–18 The potential under-
lying mechanisms for these positive results include earlier 
and therefore more effective response to emerging symp-
toms by starting supportive treatment with comedication, 
more timely dose modifications, improved detection of 
cancer recurrence and early referrals.19 20
However, these studies also have some limitations. 
The promising effects of PRO- symptom monitoring on 
HRQoL and OS have been obtained under clinical trial 
conditions with 24/7 availability of a clinical trial nurse. 
Also, these trials used an active approach in which gener-
ated alerts required direct action taken by specialised 
and trained personnel.13 14 Although this approach has 
the advantage of timely communication and subsequent 
intervention, its implementation in daily clinical prac-
tice may be hampered by high costs and a heavy logis-
tical burden. A more reactive approach, in which patients 
are instructed to act themselves instead of HCPs, may be 
easier to implement in routine/daily clinical practice.
To date, few studies have assessed whether PRO- symptom 
monitoring can be successfully implemented within daily 
clinical care, and whether a more reactive, patient- based 
approach would achieve similar results compared with an 
active approach for all patients with lung cancer.
The SYMptom monitoring with Patient- Reported 
Outcomes using a web application among patients with 
Lung cancer in the Netherlands (SYMPRO- Lung) study 
aims to test the effectiveness of PRO- symptom monitoring 
within daily clinical practice on HRQoL, by making use of 
a pragmatic stepped- wedge design. Additionally, we aim 
to compare the differential effect of an active follow- up 
approach with a reactive follow- up approach.
METHODS AND ANALYSIS
Study design
The SYMPRO- Lung study protocol is reported following 
the Standard Protocol Items: recommendations for Inter-
ventional Trials (SPIRIT) 2013. The SPIRIT checklist can 
be found as online supplemental appendix 1.21 22
The SYMPRO study uses a stepped wedge cluster design. 
This is a pragmatic design enabling insights in both the 
effect of the intervention, the implementation fidelity and 
the barriers and facilitators for implementation within daily 
clinical care. This design is characterised by the fact that 
all participating centres are randomised to one of several 
different sequences which dictate the time at which the 
centre will switch from the control period to the interven-
tion period. The main advantage of this study design is the 
fact that all centres ultimately receive the intervention condi-
tion. This guarantee of receiving the intervention allows for 
an evaluation within the context of a real- world setting in all 
participating sites. The design is typically used to evaluate 
how interventions work in real- world settings.23
To accurately reflect the general lung cancer population, 
two academic and 11 non- academic centres in the Nether-
lands are participating in this multicentre study. The centres 
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hospitals are clustered as well. Thereafter, the clusters are 
randomised for an active or reactive intervention approach. 
Each participating centre starts with including patients in the 
usual care control condition. During a total inclusion period 
of 16 months, the centres will randomly switch from the 
control to intervention condition (figures 1 and 2). Patient 
recruitment and data collection started in October 2019 and 
will end in September 2022.
Eligibility criteria
Patients are eligible to participate in the study when the 
following criteria are met:
 ► Cytologically/histologically proven or radiological 
suspect small or patients non- small cell with lung 
cancer;
 ► Starting treatment (combination) with radiotherapy, 
surgery, chemotherapy, immunotherapy, targeted 
therapy;
 ► 18 years and older;
 ► Eastern Cooperative Oncology Group (ECOG) 
Performance Status16 classification of 0, 1 or 2;
 ► Internet access.
Patients are ineligible if they meet any of the following 
criteria:
 ► Already participating in a treatment study that 
includes structured symptom reporting;
 ► A life expectancy of less than 15 weeks at time of inclu-
sion in the study;
 ► Either treatment or follow- up of a patient takes place 
in a centre that does not participate in the study.
Recruitment
Potentially eligible patients are identified by the HCP 
involved at the start of treatment. The HCP informs 
the patient about the study before starting treatment 
Figure 1 Stepped wedge cluster design.
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and provides written patient information including an 
informed consent form (and a prestamped return enve-
lope). By request, a patient can be contacted by one of 
the researchers to address additional questions. In this 
case, the patient signs a separate form and is contacted 
by telephone. On return of the informed consent, the 
patient receives an email with log- in information on using 
the web application. To provide guidance in starting with 
the study, every patient is contacted by the research team 
after returning the informed consent form, including 
patients in the control group.
Control group
Patients in the control group receive care as usual. Addi-
tionally, they will electronically complete the standard 
study questionnaires on HRQOL, patient satisfaction and 
medication adherence (table 1).
Intervention
Weekly PRO-symptom monitoring
Patients in the intervention groups (both the active 
and reactive approach) are asked to weekly report their 
symptoms and, if applicable, their oral anticancer agents 
(OACAs) use via the web application. Patients have 
access to the web application for 1 year after inclusion 
in the study and can use it on either their smartphone, 
laptop, computer or tablet. Patients are encouraged to 
use the web application minimally once weekly and maxi-
mally once daily. Adherence is encouraged by reminders 
through a push notification or email. The web applica-
tion is used in addition to the standard care provided by 
each participating centre. This study uses the web appli-
cation developed within the Patient Reported Outcomes 
Following Initial treatment and Long‐term Evaluation of 
Survivorship Registry.24 The web application is classified 
class 2a according to the European Union Medical Device 
Regulation of 2017.25 Data protection is optimised by 
hosting the web- based facility on multiprocessor servers 
for which infrastructure, configuration, license, security 
and patching are established in accordance with current 
norms (NEN- ISO/IEC 27002). Data are stored after the 
quality guidelines that are formulated in the ‘Data Seal of 
Approval’ ( www. datasealofapproval. org).
Patient-Reported Outcome version of the Common Terminology 
Criteria for Adverse Events (PRO-CTCAE)
The web application contains a subset of nine items of 
the PRO version of the Common Terminology Criteria 
for Adverse Events (PRO- CTCAE). The PRO- CTCAE 
was developed specifically for patient reporting of symp-
tomatic side effects in oncology.26 The PRO- CTCAE was 
comprehensively evaluated in English- speaking patients27 
and its translation into Dutch has recently been linguisti-
cally validated.28 The subset of the PRO- CTCAE items for 
patients with lung cancer used in this study was created 
by a mixed method study based on the European Organi-
zation for Research and Treatment of Cancer (EORTC) 
phase 1 procedure for designing questionnaires. This 
procedure includes a literature review, patient interviews 
(n=25) and interviews with HCPs (n=22).29 Based on 
these three sources a final round was organised in which 
experts selected the most relevant items for this patient 
population. It resulted in the following items: decreased 
appetite, nausea, constipation, dyspnoea, cough, general 
pain, fatigue and sad or unhappy feelings. (E. Veldhui-
jzen, unpublished work). Each item includes 1–3 ques-
tions with a five- item response scale assessing frequency, 
severity and/or interference of the symptom. In order to 
limit data collection for this study, the web application 
uses computerised adaptive testing; that is, in case the 
patient reports that (s)he has not experienced a given 
symptom, the follow- up questions are not posed. The 
five- item response scale of the PRO- CTCAE questions 
is converted to a 0–4 score. A scoring algorithm is used 
to assess the clinical toxicity grade (0–3) of the reported 
symptoms.30
Other symptoms
In addition to the selected PRO- CTCAE subset, three clin-
ically relevant items were added on recommendation of 
Dutch HCPs; weight (in kilograms), fever (body tempera-
ture above 38.5°C), diarrhoea and haemoptysis. The 
SYMPRO- Lung study uses formative evaluation as part of 
the implementation character of the study. This means 
that feedback to the study team is being used during the 
study to improve the implementation and the willingness 
for the users to adopt this new approach. The SYMPRO 
study team has decided to add the item ‘diarrhoea’ 
based on expert opinions during the startup phase of the 
study. During immunotherapy, diarrhoea is considered a 
required symptom that HCPs want to monitor. Therefore, 
it was decided to add this item to the core subset after 3 
months following study initiation.
Additionally, open fields are available where patients 
can report the presence and severity of any other symptom 
in the same manner as the PRO- CTCAE items. Lastly, 
there is an open field where patients can add additional 
comments. For safety reasons, patients are instructed to 
call the hospital immediately in case of an emergency (the 
usual instructions) and also to contact the HCP when in 
doubt about any of their symptoms.
Alerts and reports
An alert indicating the need for intervention is triggered 
when the predefined conditions are met (table 2). The 
weekly PROs are visualised in a report including graphs of 
the course of symptoms over time. This report was devel-
oped with the input of web designers, and was pilot tested 
in both patients (n=6) and HCPs (n=4) using the think- 
aloud method. Both patients and HCPs can download 
the report. The HCP report consists of three consecutive 
tabs with successive degree of detail; (1) overview of the 
symptoms that triggered an alert, (2) the sum score of all 
queried symptoms over time and (3) the response to each 
symptom item over time. For the feasibility, a single ques-
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Table 1 Study outcome measures and timing
Variable Measure Details Assessment
Sociodemographic data Patient report  ► Comorbidity, education, employment status, marital status T0
Primary outcome
Health- related quality of life




 ► 30 items, 4 point scale
 ► Score range: 0–100 (sum score)
 ► Time frame: 1 week
 ► The summary score will be calculated as the mean of the 
combined 13 QLQ- C30 scale scores (excluding financial 
impact and a two- item global quality of life scale).
 ► All included scale scores will be reversed so that higher 
scores indicate improved outcomes
T0, T1, T2, T3
Quality of life for lung cancer EORTC QLQ 
LC-13
 ► 13 items, 4 point scale
 ► Score range:
 ► Time frame: 1 week
T0, T1, T2, T3
Secondary outcomes
Progression free survival and overall survival
PFS and OS Clinical data 
HCP/NKR
 ► Stable disease, recurrence or death.
 ► PFS and OS are defined from start of treatment until 
recurrence or date of death.
T1, T2, T3
Medication adherence (only measured in patients using OACAs)






Medication Adherence Report Scale (MARS-5)
 ► 5 items, 5 point scale
 ► Score range: 5–25
 ► A score of >25 points will be considered therapy adherent.
 ► Time frame: current behaviour
T1, T2
Patients’ beliefs about OACA BMQ- specific Beliefs about Medicines Questionnaire specific
 ► 10 items, 5 point scale
 ► Subscale: necessity and concern
 ► Score range per subscale: 5–25
 ► Time frame: current
T2
HCPs perception about 
medication adherence 
and activities aimed at the 
improvement of medication 
adherence
HCP Perceptions of adherence management questions
 ► 5 items, 5 point Likert- scale
 ► Score range: 0–5
 ► Time frame: current
The adapted, care usually provided in supporting adherence to 
treatment with OACA- list
 ► 18 items, 2 point scale
 ► Max score: 18
 ► Time frame: past 6 months
T0, T3
Cost- effectiveness
Quality of life in general 
(description of one’s 






 ► 5 items, 5 levels
 ► Time frame: today
 ► For the cost- effectiveness analysis we will use the EQ- 5D- 5L 
to obtain utilities
T0, T1, T2, T3
Implementation fidelity
Evaluation of the app PRO  ► 13 items
 ► Open and closed ended questions (eg, likert scales) to 
assess how the app is evaluated.
 ► Higher scores indicate better evaluation
 ► Time frame: current attitude
 ► Based on the MIDI46
T1, T3
HCP  ► 8 items
 ► Open and closed ended questions (eg, likert scales) to 
assess how the app is evaluated.
 ► Higher scores indicate better evaluation
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the type of action taken as a result of the alert (eg, no 
action needed, extra (phone) consult, referral to General 
Practitioner (GP), psychological help, emergency depart-
ment or other action).
The active versus the reactive intervention approach
The active and reactive approach differs in the way the 
alerts are handled. In the active approach, the HCP 
receives an alert via a (secured) email and is instructed 
to contact the patient within 24 hours during office hours 
on weekdays, to perform triage, give tailored advice and 
to intervene when needed (eg, a visit to the hospital, 
comedication, etc). In the reactive approach, the patient 
receives an alert via a pop- up notification and an email 
with the advice to contact the hospital within 24 hours on 
weekdays.
If a patient does not complete the weekly symptom 
monitoring subset for four consecutive weeks, a 
researcher contacts the patient by email or telephone to 
check whether (s)he is experiencing any problems with 
using the web application.
Medication adherence
For patients treated with OACAs, the web application 
monitors medication adherence by asking whether 
the patient has taken his/her medication in the past 
week (yes/no). A ‘no’ is considered non- adherent and 
in that case, patients are asked to clarify the reason for 
Variable Measure Details Assessment
Patient satisfaction with care PRO  ► 3 items, 5 point scale
 ► Score range: 3–15
 ► Higher scores indicate higher satisfaction
 ► Time frame: current attitude
T1, T3
Treatment adjustments Clinical data 
HCP
 ► 3 questions if the treatment has been altered do to the 
reported symptoms
 ► 3 questions if patients have chosen to not contact their HCP 
after an alert (only for the reactive group)
T1
Implementation fidelity Semistructured 
interviews
 ► Interviews with patients and HCPs to evaluate the 
implementation and use of the app, topic list based on the 
MIDI46
T1, T3
BMQ, Beliefs about Medicine Questionnaire; EORTC QLQ C30, European Organization for Research and Treatment of Cancer Quality of 
Life Questionnaire Cancer 30 items; EORTC QLQ LC-13, European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire Lung Cancer 13 items; EQ- 5D- 5L, European Quality of Life Scale-5 Dimensions with 5 Levels; HCP, healthcare provider; 
MIDI, Measurement Instrument for Determinants of Innovations; NKR, Netherlands Cancer Registry; OACAs, oral anticancer agents; OS, 
overall survival; PFS, progression- free survival; PRO, patient- reported outcome.
Table 1 Continued
Table 2 Set of predefined rules to trigger an alert
Symptom Rules for alert
PRO- CTCAE symptoms
Decreased appetite 1. If the symptom reaches grade 3
a. The symptom has not reached a grade 3 in the last 2 weeks (<15 days)
b. If the symptom stays a stable grade 3 for 4 consecutive weeks, the fourth week will provide the 
next alert
2. If the symptom worsens by ≥2 grades
a. in 2 weeks







Sad or unhappy feelings
General pain
Other symptoms
Fever 3. If ‘yes’ is scored (independent of earlier reports about fever)
Haemoptysis 4. If ‘a little’ or ‘a lot’ is scored (independent of earlier reports about haemoptysis)
Weight 5. Loss of weight ≥3 kg in 1 or 2 weeks
a. If the questionnaire was not filled- in for 4 consecutive weeks a loss of weight of ≥3 kg since the 
last measurement will also summon an alert
b. Patient has scored ‘I did not weight myself’ is seen as rule 5a
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non- adherence (forgotten, instructed by the doctor, 
decided not to take the medication or other). When a 
patient is non- adherent, the web application automati-
cally advises the patient to discuss this during their next 
consultation with the HCP.
Patient and public involvement
Patients were involved in the design of the web applica-
tion. Study participants receive emails every 3 months to 
update them about the progress of the project.
Outcomes
Primary outcome measure
The primary outcome is the mean difference between 
HRQoL at baseline (T0) and 15 weeks (T1), 6 months 
(T2) and 12 months (T3) post baseline between the inter-
vention and control groups. HRQoL is measured by the 
EORTC QLQ- C30.31 The Quality of Life Questionnaire 
Cancer 30 items (QLQ- C30) summary score is calculated 
as the mean of the combined 13 QLQ- C30 scale scores 
(excluding financial impact and a two- item global quality 
of life scale).32 Our main HRQoL endpoints are physical 
functioning and the QLQ- C30 summary score. We chose 
the QoL summary score and physical functioning domain 
because they recently showed to be a more robust measure 
of HRQoL over the global QOL domain. Furthermore, a 
recent study of Husson et al also showed that both the 
summary score as well as physical functioning had more 
prognostic value than the global QoL domain.33
Secondary outcome measures
See table 1 for an overview of all outcome measurements 
and timing secondary outcome measures include:
 ► 1- year progression- free survival (PFS);
 ► 1- year OS;
 ► 1- year recurrence rate;
 ► Symptom incidence and severity over time (PRO- 
CTCAE for the intervention group only and EORTC 
QLQ lung module-13 for both groups);
 ► Medication adherence (OACA) (Medication Adher-
ence Report Scale-5) and Believes about Medicine 
Questionnaire;34 35
 ► Cost- effectiveness (Euroqol-5 Dimensions with 5 levels 
(EQ- 5D- 5L)36 and clinical healthcare costs data);
 ► Implementation fidelity (intervention group only; 
quantitative and qualitative patient and HCP 
reported).
Timing of measurements
The standard study questionnaires on HRQoL, medica-
tion adherence (if applicable) and patient satisfaction 
with care are collected in all groups at baseline, 15 weeks, 
6 months and 12 months after the start of the treatment 
via the web application (table 1).
Sociodemographic and clinical data
All data were recorded electronically. At baseline, 
patients are asked to report their demographic charac-
teristics (education, employment status, marital status) 
and comorbidity. HCPs report treatment characteristics 
(ECOG Performance Status, histological tumour type, 
cancer stage according to the Tumour, Nodes, Metastases 
(TNM) eighth edition and (previous) treatment) at base-
line. During the follow- up assessments at 15 weeks, 6 and 
12 months, the HCPs are asked to report ECOG Perfor-
mance Status, current treatment and treatment response 
(ie, cured, complete or partial response, stable disease, 
progression, relapse, death and or other).
Other observational data (OS, direct medical costs 
including, CT scans, hospital admissions and emergency 
room visits) will be retrieved from the Netherlands Cancer 
Registry and Dutch Hospital Data).
Statistical considerations
Randomisation
Randomisation between the active and reactive group is 
performed upfront using the independent randomisa-
tion tool provided by CASTOR Electronic Data Capture 
(EDC).37 The randomisation follows a stratified randomi-
sation procedure, accounting for (1) an even distribution 
of the type of centre (academic/non- academic centre) 
and (2) a similar intervention approach in centres that 
collaborate when referring patients.
Sample size calculation
We based our power calculation on two main assumptions;
1. We want to demonstrate superiority in patient- reported 
symptom monitoring compared with care as usual with 
a minimum HRQoL benefit of 0.4 (effect size (ES)).
2. We want to demonstrate non- inferiority between the 
active and reactive intervention approach, with a max-
imum HRQoL difference of 0.2 ES between the active 
and the reactive approach.
Our trial is powered to demonstrate a clinically rele-
vant ES of 0.4 between the intervention and control 
group (80% power (β), with a one- sided alpha (α) of 5%, 
compared with the trial of Basch et al.14 To detect an ES 
of 0.4 (β 0.80, α 0.05) in HRQoL, inclusion of at least 
148 control and 148 intervention patients (74 patients 
in the active and 74 patients in the reactive approach) is 
required. Since our study entails a stepped wedge cluster 
design, we need to account for within- centre clustering. 
Assuming an intraclass correlation coefficient (ICC) of 
.025, the design effect ((1+(6−1)*ICC)) is 1.125 and the 
necessary sample size for the clustered study is therefore 
inflated to respectively 167 and 168 patients (84 per study 
arm).
To demonstrate non- inferiority between the active 
and reactive approach, we require an ES of less than 0.2 
between the two approaches. This necessitates at least 146 
patients per intervention arm. This means that a total of 
292 patients in the control group and 146 patients per 
intervention group are needed to be included in the trial.
The stepped wedge design is used to implement the 
intervention in 13 centres (clusters). Based on the 
average number of newly diagnosed patients plus the 
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therapy in the participating centres, we expect to enrol 
an average of 5 patients per centre per 5 weeks (1 patient 
per week). Therefore, the average length of the steps is 5 
weeks. Given this expected step length and the number of 
participating clusters, the follow- up period is 16.1 months 
(70 weeks) with 55 control clusters, 28 active intervention 
clusters and 27 reactive intervention clusters.
For the primary endpoint, the analyses will be strati-
fied for the active and reactive approach. Therefore, the 
study consists of three groups; control, active approach 
and reactive approach. If one of the intervention 
approaches is significantly associated with an improved 
HRQoL compared with the control group, this interven-
tion will be favoured for broader implementation. When 
both interventions are significantly better compared 
with the control group, the decision to favour a certain 
approach will be based on the estimated difference in 




Baseline characteristics of the patients in the control 
and intervention groups will be compared using a χ2 
test for categorical data and an independent samples 
Student’s t- test for normally distributed variables or a 
non- parametric Wilcoxon signed- rank test for continuous 
variables with a skewed distribution (two sides, p=0.05).
Primary analyses will be performed on an intention- to- 
treat basis. Mean differences in HRQoL between baseline 
and post- treatment measurements will be compared using 
independent samples t- tests (in case of a normal distribu-
tion) or a Wilcoxon signed rank- test (in case of a skewed 
distribution). Missing data on HRQoL will be imputed 
using multiple imputation. Differences in HRQoL over 
time between the groups will be compared using linear 
mixed modelling analyses, accounting for within- centre 
clustering and potential time effects. The final model will 
be adjusted for potential confounders known from scien-
tific literature, such as age, sex, educational level, comor-
bidities and disease characteristics. Statistical significance 
level is defined as p<0.05.
Kaplan- Meier curves with log- rank two- sided tests will 
be used to compare OS and PFS of the intervention 
versus control group, also stratifying for the active versus 
reactive intervention group. Cox proportional hazard 
analyses will be performed to estimate the effect of PRO- 
symptom monitoring on OS and PFS, adjusting for poten-
tial confounding.
The association between baseline characteristics and 
medication adherence over time will be analysed using 
generalised estimating equations. An incremental cost–
utility ratio (ICUR) will be calculated to measure the 
cost per gained quality- adjusted life year (QALY). The 
ICUR will be calculated by dividing the incremental costs 
by the incremental QALYs using the formula: ICUR = 
(Costs_intervention – Costs_control)/(QALYinterven-
tion − QALYcontrol). Total costs will be calculated using 
a healthcare perspective, including intervention costs 
and direct medical costs. If available, direct medical costs 
will be calculated by multiplying resource use by inte-
gral cost prices as presented in the Dutch Health Care 
Insurance Board guidelines on cost studies.38 The utility 
scores linked to the various health states of the EQ- 5D39 
will be used to calculate QALYs by weighing the length of 
time spent in a particular health condition by the utility. 
Missing data on direct medical costs and utilities measured 
using the EQ- 5D- 5L will be imputed using multiple impu-
tation. Because follow- up of the study is approximately 
1 year, neither costs nor effects will be discounted. The 
uncertainty surrounding the ICUR will be assessed using 
bootstrapping with 5000 replications and projected on a 
cost–utility plane. In addition, cost–utility acceptability 
curves will be presented and sensitivity analyses will be 
performed, focusing on uncertainty around the most 
important cost parameters.
Qualitative data
To evaluate the app and assess the implementation fidelity, 
interviews will be conducted with both patients and HCPs. 
Patients and HCPs, from each centre who agreed to be 
contacted for an interview will be approached after 15 
weeks and 1 year until data saturation is reached. These 
interviews are guided by a topic list based on the frame-
work for implementation fidelity40 41 and by the results of 
the evaluation of the web application questionnaire at 15 
weeks. The interviews will be audiotaped and transcribed.
The transcripts will be evaluated by use of the frame-
work approach for (inductive) thematic analysis.42 Two 
independent researchers will openly code the data. In 
this analysis we will focus on the topics in our topic list. 
Differences are discussed until consensus is achieved. 
Qualitative data are analysed using  Atlas. ti software V.7 
(GmbH, Berlin).
Quotes from the qualitative interviews will be used to 
illustrate the quantitative data.
ETHICS AND DISSEMINATION
The study protocol (24 March 2021, V.10) has been 
approved by the Institutional Review Board and Medical 
Ethical Committee (METC) of the Amsterdam UMC, 
location VUmc (under number NL 68440.029.18), as 
well as by the review boards of all participating centres. 
Amendments are changes made to the research methods 
after approval by the accredited METC. All amendments 
are notified to the METC, principal investigators from 
each participating institution, and to the trial register 
(https://www. trialregister. nl/).
This study will be conducted according to the princi-
ples of Good Clinical Practice and General Data Protec-
tion Regulation.
A written informed consent is obtained from all 
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DISCUSSION
This study is hypothesised to demonstrate the beneficial 
effects of electronic PRO- symptom monitoring in daily clin-
ical care on the HRQoL of patients with lung cancer. In 
addition, due to the pragmatic stepped wedge design and 
inclusion of a reactive approach, it gives more insights in 
the most feasible and effective approach for use of PRO- 
monitoring within daily clinical care. Moreover, barriers and 
facilitators of the implementation process are investigated.
The study has several core strengths. First, the use of a 
more pragmatic stepped wedge cluster design allows all 
participating centres to implement the intervention and the 
centres provide data in both the control and intervention 
period, and accordingly act as their own control.43 Second, 
the use of items from the Food and Drug Administration 
(FDA)- approved PRO- CTCAE is a perfect fit to the CTCAE, 
which is widely used in daily clinical oncology care to report 
symptomatic adverse events. Third, this multicentre study 
includes patients with lung cancer of all stages and treatment 
options from 13 centres, which provides a heterogeneous 
group comparable to real- world clinical practice. Last, the 
evaluation of the implementation fidelity of the active inter-
vention and newly designed reactive intervention approach, 
and the cost- effectiveness evaluation, will create insight into 
the barriers and facilitators of efficient implementation of 
PRO- toxicity monitoring within daily clinical care. There-
fore, this study will provide considerable knowledge on 
whether PRO- symptom monitoring is not only feasible, but 
also cost- effective in a real- world clinical setting. We expect 
to be able to inform future policy making about the most 
efficient ways to use PRO- symptom monitoring alongside 
clinical care in patients with (lung) cancer. Although devel-
oped for patients with lung cancer, this project will serve as a 
template for other diseases and situations.
There are several limitations of the study that need to 
be addressed. First, most participating centres do not allow 
to fully integrate the web application within the electronic 
health record, making it more difficult to use by HCPs 
during consultations. This might decrease the uptake of 
the intervention; however, this is a first step towards imple-
menting PRO- symptom monitoring in standard lung cancer 
care in the Netherlands. Second, the web application is not 
a downloadable mobile application, potentially hindering 
user experience and ease of use. However, the web appli-
cation is designed specifically for this target group and was 
tested by patients with lung cancer prior to the interven-
tion. Therefore, we expect this to have a small effect on user 
experience and ease of use. Lastly, since direct feedback is a 
fundamental part of the intervention, paper surveys are not 
offered as an alternative. Therefore internet access can be 
a barrier for participation by patients of older age. We esti-
mate this problem to be minimal since internet was present 
in 98% of the Dutch households in 2017.44 In 2016, 84% of 
the Dutch population aged 65–75 years, and 51% of age 75 
years and older made use of internet.45
In conclusion, the SYMPRO- trial aims to evaluate the 
effect of PRO- symptom monitoring during and after lung 
cancer treatment on HRQoL. It is anticipated that such an 
approach will have direct benefits on a patient’s HRQoL and 
potentially also on PFS and OS. If successful, this study may 
provide hands- on guidelines on how to efficiently imple-
ment PRO- symptom monitoring within daily clinical care, 
and thereby enhance clinical outcomes of patients with lung 
cancer by improved symptom management.
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adjusted analyses) 
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statistical methods to handle missing data (eg, multiple 
imputation) 
11, 12 
Methods: Monitoring  
Data monitoring 21a Composition of data monitoring committee (DMC); 
summary of its role and reporting structure; statement 
of whether it is independent from the sponsor and 
competing interests; and reference to where further 
details about its charter can be found, if not in the 
protocol. Alternatively, an explanation of why a DMC is 
not needed 
Not applicable 
 21b Description of any interim analyses and stopping 
guidelines, including who will have access to these 
interim results and make the final decision to terminate 
the trial 
Not applicable 
Harms 22 Plans for collecting, assessing, reporting, and 
managing solicited and spontaneously reported 
adverse events and other unintended effects of trial 
interventions or trial conduct 
Not applicable 
Auditing 23 Frequency and procedures for auditing trial conduct, if 
any, and whether the process will be independent from 
investigators and the sponsor 
Not applicable 
Ethics and dissemination  
Research ethics 
approval 
24 Plans for seeking research ethics 
committee/institutional review board (REC/IRB) 
approval 
14,15 
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25 Plans for communicating important protocol 
modifications (eg, changes to eligibility criteria, 
outcomes, analyses) to relevant parties (eg, 
investigators, REC/IRBs, trial participants, trial 
registries, journals, regulators) 
15 
Consent or assent 26a Who will obtain informed consent or assent from 
potential trial participants or authorised surrogates, and 
how (see Item 32) 
7,15 
 26b Additional consent provisions for collection and use of 
participant data and biological specimens in ancillary 
studies, if applicable 
Not applicable 
Confidentiality 27 How personal information about potential and enrolled 
participants will be collected, shared, and maintained in 





28 Financial and other competing interests for principal 
investigators for the overall trial and each study site 
15 
Access to data 29 Statement of who will have access to the final trial 
dataset, and disclosure of contractual agreements that 




30 Provisions, if any, for ancillary and post-trial care, and 





31a Plans for investigators and sponsor to communicate 
trial results to participants, healthcare professionals, 
the public, and other relevant groups (eg, via 
publication, reporting in results databases, or other 
data sharing arrangements), including any publication 
restrictions 
15 
 31b Authorship eligibility guidelines and any intended use 
of professional writers 
16 
 31c Plans, if any, for granting public access to the full 
protocol, participant-level dataset, and statistical code 
Not applicable 
Appendices    
Informed consent 
materials 
32 Model consent form and other related documentation 




33 Plans for collection, laboratory evaluation, and storage 
of biological specimens for genetic or molecular 
analysis in the current trial and for future use in 
ancillary studies, if applicable 
Not applicable 
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*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 
Explanation & Elaboration for important clarification on the items. Amendments to the 
protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT 
Group under the Creative Commons “Attribution-NonCommercial-NoDerivs 3.0 Unported” 
license. 
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Appendix 1: Informed consent form participant active group 
 
SYMPRO-Lung 
Official title: “SYMptom monitoring with Patient-Reported Outcomes using a web application 
among LUNG cancer patients in the Netherlands.” 
 
• I have read the information letter. I was also able to ask questions. My questions have been 
answered sufficiently. I had enough time to decide whether to participate. 
• I know that participating is voluntary. I also know that I can decide at any time not to participate 
or to withdraw from the study. I don't have to give a reason for withdrawal. 
• I give permission to inform my general practitioner that I am participating in this study. 
• I give permission for the collection and use of my data to answer the research questions of this 
research. 
• I authorize the researchers of the Amsterdam UMC, location VUmc, to request my medical and 
personal data from my treating hospital and for the hospital to provide these data to the 
researchers of the Amsterdam UMC, location VUmc. 
• I know that for the purpose of verifying the study, some people may have access to all my data. 
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Please fill in all the fields below 
 
□ I do 
□ I do not 
give permission to use my data for future lung cancer research or app development. 
 
□ I do 
□ I do not 
give permission to contact me for an interview about the evaluation of the app. 
 
•        I agree to participate in this study. 
 
 
Name: Mr. /Mrs.:* __________________________________________________________________ 
 
E-mail address: _____________________________________________________________________ 
 








 * Strike off what does not apply 
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To be completed by the doctor/researcher: 
 
I declare that I have fully informed the participant about the study. 
 
If information becomes known, during the research, that could influence the consent of the 
participant, I will inform him/her in good time. 
 
Name of doctor/researcher (or representative): ________________________________________ 
 














The participant will receive a complete information letter, along with a signed version of the consent 
form. 
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Description Addressed on  
Page number 
Administrative information  
Title 1 Descriptive title identifying the study design, 
population, interventions, and, if applicable, trial 
acronym 
1 
Trial registration 2a Trial identifier and registry name. If not yet registered, 
name of intended registry 
2 
2b All items from the World Health Organization Trial 
Registration Data Set 
Not applicable 
Protocol version 3 Date and version identifier 1 





5a Names, affiliations, and roles of protocol contributors 1 
5b Name and contact information for the trial sponsor 1 
 5c Role of study sponsor and funders, if any, in study 
design; collection, management, analysis, and 
interpretation of data; writing of the report; and the 
decision to submit the report for publication, including 
whether they will have ultimate authority over any of 
these activities 
15 
 5d Composition, roles, and responsibilities of the 
coordinating centre, steering committee, endpoint 
adjudication committee, data management team, and 
other individuals or groups overseeing the trial, if 
applicable (see Item 21a for data monitoring 
committee) 
Not applicable 
Introduction    
Background and 
rationale 
6a Description of research question and justification for 
undertaking the trial, including summary of relevant 
studies (published and unpublished) examining 
benefits and harms for each intervention 
4,5 
 6b Explanation for choice of comparators 4,5,9 - 11 
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 2 
Objectives 7 Specific objectives or hypotheses 5 
Trial design 8 Description of trial design including type of trial (eg, 
parallel group, crossover, factorial, single group), 
allocation ratio, and framework (eg, superiority, 
equivalence, noninferiority, exploratory) 
6 
Methods: Participants, interventions, and outcomes  
Study setting 9 Description of study settings (eg, community clinic, 
academic hospital) and list of countries where data will 
be collected. Reference to where list of study sites can 
be obtained 
6 
Eligibility criteria 10 Inclusion and exclusion criteria for participants. If 
applicable, eligibility criteria for study centres and 
individuals who will perform the interventions (eg, 
surgeons, psychotherapists) 
6 
Interventions 11a Interventions for each group with sufficient detail to 
allow replication, including how and when they will be 
administered 
7 - 9 
11b Criteria for discontinuing or modifying allocated 
interventions for a given trial participant (eg, drug dose 
change in response to harms, participant request, or 
improving/worsening disease) 
Not applicable 
11c Strategies to improve adherence to intervention 
protocols, and any procedures for monitoring 
adherence (eg, drug tablet return, laboratory tests) 
7 
11d Relevant concomitant care and interventions that are 
permitted or prohibited during the trial 
Not applicable 
Outcomes 12 Primary, secondary, and other outcomes, including the 
specific measurement variable (eg, systolic blood 
pressure), analysis metric (eg, change from baseline, 
final value, time to event), method of aggregation (eg, 
median, proportion), and time point for each outcome. 
Explanation of the clinical relevance of chosen efficacy 




13 Time schedule of enrolment, interventions (including 
any run-ins and washouts), assessments, and visits for 
participants. A schematic diagram is highly 
recommended (see Figure) 
Figure 1,2 
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 3 
Sample size 14 Estimated number of participants needed to achieve 
study objectives and how it was determined, including 
clinical and statistical assumptions supporting any 
sample size calculations 
10, 11 
Recruitment 15 Strategies for achieving adequate participant 
enrolment to reach target sample size 
7 
Methods: Assignment of interventions (for controlled trials)  
Allocation:    
Sequence 
generation 
16a Method of generating the allocation sequence (eg, 
computer-generated random numbers), and list of any 
factors for stratification. To reduce predictability of a 
random sequence, details of any planned restriction 
(eg, blocking) should be provided in a separate 
document that is unavailable to those who enrol 





16b Mechanism of implementing the allocation sequence 
(eg, central telephone; sequentially numbered, opaque, 
sealed envelopes), describing any steps to conceal the 
sequence until interventions are assigned 
Not applicable 
Implementation 16c Who will generate the allocation sequence, who will 





17a Who will be blinded after assignment to interventions 
(eg, trial participants, care providers, outcome 
assessors, data analysts), and how 
Not applicable 
 17b If blinded, circumstances under which unblinding is 
permissible, and procedure for revealing a participant’s 
allocated intervention during the trial 
Not applicable 
Methods: Data collection, management, and analysis  
Data collection 
methods 
18a Plans for assessment and collection of outcome, 
baseline, and other trial data, including any related 
processes to promote data quality (eg, duplicate 
measurements, training of assessors) and a 
description of study instruments (eg, questionnaires, 
laboratory tests) along with their reliability and validity, 
if known. Reference to where data collection forms can 
be found, if not in the protocol 
7 - 10 
 18b Plans to promote participant retention and complete 
follow-up, including list of any outcome data to be 
collected for participants who discontinue or deviate 
from intervention protocols 
Not applicable 
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19 Plans for data entry, coding, security, and storage, 
including any related processes to promote data quality 
(eg, double data entry; range checks for data values). 
Reference to where details of data management 




20a Statistical methods for analysing primary and 
secondary outcomes. Reference to where other details 
of the statistical analysis plan can be found, if not in the 
protocol 
11, 12 
 20b Methods for any additional analyses (eg, subgroup and 
adjusted analyses) 
11, 12 
 20c Definition of analysis population relating to protocol 
non-adherence (eg, as randomised analysis), and any 
statistical methods to handle missing data (eg, multiple 
imputation) 
11, 12 
Methods: Monitoring  
Data monitoring 21a Composition of data monitoring committee (DMC); 
summary of its role and reporting structure; statement 
of whether it is independent from the sponsor and 
competing interests; and reference to where further 
details about its charter can be found, if not in the 
protocol. Alternatively, an explanation of why a DMC is 
not needed 
Not applicable 
 21b Description of any interim analyses and stopping 
guidelines, including who will have access to these 
interim results and make the final decision to terminate 
the trial 
Not applicable 
Harms 22 Plans for collecting, assessing, reporting, and 
managing solicited and spontaneously reported 
adverse events and other unintended effects of trial 
interventions or trial conduct 
Not applicable 
Auditing 23 Frequency and procedures for auditing trial conduct, if 
any, and whether the process will be independent from 
investigators and the sponsor 
Not applicable 
Ethics and dissemination  
Research ethics 
approval 
24 Plans for seeking research ethics 
committee/institutional review board (REC/IRB) 
approval 
14,15 
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25 Plans for communicating important protocol 
modifications (eg, changes to eligibility criteria, 
outcomes, analyses) to relevant parties (eg, 
investigators, REC/IRBs, trial participants, trial 
registries, journals, regulators) 
15 
Consent or assent 26a Who will obtain informed consent or assent from 
potential trial participants or authorised surrogates, and 
how (see Item 32) 
7,15 
 26b Additional consent provisions for collection and use of 
participant data and biological specimens in ancillary 
studies, if applicable 
Not applicable 
Confidentiality 27 How personal information about potential and enrolled 
participants will be collected, shared, and maintained in 





28 Financial and other competing interests for principal 
investigators for the overall trial and each study site 
15 
Access to data 29 Statement of who will have access to the final trial 
dataset, and disclosure of contractual agreements that 




30 Provisions, if any, for ancillary and post-trial care, and 





31a Plans for investigators and sponsor to communicate 
trial results to participants, healthcare professionals, 
the public, and other relevant groups (eg, via 
publication, reporting in results databases, or other 
data sharing arrangements), including any publication 
restrictions 
15 
 31b Authorship eligibility guidelines and any intended use 
of professional writers 
16 
 31c Plans, if any, for granting public access to the full 
protocol, participant-level dataset, and statistical code 
Not applicable 
Appendices    
Informed consent 
materials 
32 Model consent form and other related documentation 




33 Plans for collection, laboratory evaluation, and storage 
of biological specimens for genetic or molecular 
analysis in the current trial and for future use in 
ancillary studies, if applicable 
Not applicable 
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*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 
Explanation & Elaboration for important clarification on the items. Amendments to the 
protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT 
Group under the Creative Commons “Attribution-NonCommercial-NoDerivs 3.0 Unported” 
license. 
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Appendix 1: Informed consent form participant active group 
 
SYMPRO-Lung 
Official title: “SYMptom monitoring with Patient-Reported Outcomes using a web application 
among LUNG cancer patients in the Netherlands.” 
 
• I have read the information letter. I was also able to ask questions. My questions have been 
answered sufficiently. I had enough time to decide whether to participate. 
• I know that participating is voluntary. I also know that I can decide at any time not to participate 
or to withdraw from the study. I don't have to give a reason for withdrawal. 
• I give permission to inform my general practitioner that I am participating in this study. 
• I give permission for the collection and use of my data to answer the research questions of this 
research. 
• I authorize the researchers of the Amsterdam UMC, location VUmc, to request my medical and 
personal data from my treating hospital and for the hospital to provide these data to the 
researchers of the Amsterdam UMC, location VUmc. 
• I know that for the purpose of verifying the study, some people may have access to all my data. 









BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2021-052494:e052494. 11 2021;BMJ Open, et al. Billingy NE
Please fill in all the fields below 
 
□ I do 
□ I do not 
give permission to use my data for future lung cancer research or app development. 
 
□ I do 
□ I do not 
give permission to contact me for an interview about the evaluation of the app. 
 
•        I agree to participate in this study. 
 
 
Name: Mr. /Mrs.:* __________________________________________________________________ 
 
E-mail address: _____________________________________________________________________ 
 








 * Strike off what does not apply 
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To be completed by the doctor/researcher: 
 
I declare that I have fully informed the participant about the study. 
 
If information becomes known, during the research, that could influence the consent of the 
participant, I will inform him/her in good time. 
 
Name of doctor/researcher (or representative): ________________________________________ 
 














The participant will receive a complete information letter, along with a signed version of the consent 
form. 
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